SARS-CoV-2 Spike Peptid
Reaktivität: SARS Coronavirus-2 (SARS-CoV-2)
Wirt: Synthetic
InhA
2 Abbildungen
(3 Referenzen)-
- Target Alle SARS-CoV-2 Spike Produkte
- SARS-CoV-2 Spike
- Spezies
- SARS Coronavirus-2 (SARS-CoV-2)
-
Quelle
- Synthetic
- Applikation
- Inhibition Assay (InhA)
- Sequenz
- DISGINASVV NIQKEIDRLN EVAKNLNESL IDLQEL
- Produktmerkmale
- 2019-nCov-HR2P
- Reinheit
- ≥ 95 %
- Bestandteile
- Each vial contains 100 μg of NET peptide.
-
SARS-CoV-2 Spike peptide
Reaktivität: SARS Coronavirus-2 (SARS-CoV-2) Wirt: Synthetic InhA
SARS-CoV-2 Spike peptide (Cy5)Reaktivität: SARS Coronavirus-2 (SARS-CoV-2) Wirt: Synthetic InhA
SARS-CoV-2 Spike peptide (Cy5)Reaktivität: SARS Coronavirus-2 (SARS-CoV-2) Wirt: Synthetic InhA
-
- Applikationshinweise
- Optimal working dilution should be determined by the investigator.
- Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Format
- Powder
- Lagerung
- RT,4 °C,-20 °C
- Informationen zur Lagerung
- Up to 6 months in lyophilized form at 0-5°C. For best results, rehydrate just before use. After rehydration, keep solution at -20°C for up to 3 months. Aliquot before freezing to avoid repeated freeze-thaw cycles.
-
-
: "Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein." in: Cellular & molecular immunology, (2020) (PubMed).
: "Drug treatment options for the 2019-new coronavirus (2019-nCoV)." in: Bioscience trends, Vol. 14, Issue 1, pp. 69-71, (2020) (PubMed).
: "A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike." in: Science advances, Vol. 5, Issue 4, pp. eaav4580, (2019) (PubMed).
-
: "Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein." in: Cellular & molecular immunology, (2020) (PubMed).
-
- Target
- SARS-CoV-2 Spike
- Synonyme
- E2 Peptide, E2 glycoprotein precursor Peptide, Surface Glycoprotein Peptide, S Peptide
- Substanzklasse
- Viral Protein
- Molekulargewicht
- 4008.50
- Gen-ID
- 43740568
- UniProt
- P0DTC2
-
Sie sind hier:
